Skip to main content
Quest Diagnostics

Oncology

The power of precision

From early detection screening to diagnosis, monitoring, and beyond, our oncology portfolio provides critical insights that enable your lab to support clinical goals to deliver personalized care for a full range of solid tumor cancers, hematology, and hereditary cancers.

Quest is committed to helping you reach your precision oncology goals through advanced diagnostic tests. That’s why we invest in progressive solutions that help increase diagnostic accuracy and increase organizational quality. See below for some of the featured advancements you can count on from Quest.

  • Haystack MRD® is an advanced tumor-informed minimal residual disease (MRD) test that detects circulating tumor DNA (ctDNA) in blood using proprietary technology that checks both DNA strands for each variant
  • Exceptional accuracy for more precise, informed clinical choices across diverse clinical applications; superb sensitivity and specificity translate to better MRD detection for greater confidence when making key clinical decisions
  • 95% limit of detection at 0.0006% tumor fraction means that patients who recur may be identified earlier than with traditional methods
  • Applications include neoadjuvant response, residual disease detection, treatment response assessment, and recurrence surveillance 

  • Whole-slide imaging enables viewing of patient specimens in new ways, allowing not just faster review but potentially greater diagnostic insight to improve naming, staging, and grading of disease
  • Powerful tools to assist pathologists, including validated artificial intelligence (AI) algorithms that enable automated image analysis for qualification and quantification of tissue samples, aiding in the precision and grading of the final diagnosis performed by board certified pathologists
  • Fast virtual connection with leading pathologists within and outside your health system network to support improved patient care

  • Our resource committees cover 400+ subspecialties, from hematopathology to molecular and solid tumor pathology
  • Pathologist best-practice teams can recommend changes or additions to ensure your oncology portfolio is relevant to your needs
  • Our technical component/professional component (TC/PC) solutions can augment your existing services with CLIA-certified labs, dedicated project managers, and more
See our entire oncology test portfolio 

Innovation with a purpose

Gaining access to esoteric and routine tests from one comprehensive diagnostics provider can help your lab save time and money while driving operational efficiencies.
oncology testing

Expand your oncology portfolio

Tap into extensive oncology testing from a single best-in-class diagnostic service.

Let's talk

Lab testing by specialty

Solutions

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.